---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-007794"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T08:03:32.252264+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech extends Meteora FPA valuation to Dec 2026, adds $372k AlpineBrook debt

## Summary
- Eighth FPA amendment with Meteora extends Valuation Date to December 31, 2026.
- AlpineBrook Second Amendment increases secured note principal by $372,000 to $26,507,106.
- Interest on the new $372,000 loan accrues from January 23, 2026.
- Borrowers agree to use best efforts to negotiate convertible loan consolidation with AlpineBrook.
- Borrowers must give AlpineBrook 24-hour pre-review of any public disclosure involving the lender.

## SEC filing metadata
- accession: 0001213900-26-007794
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390026007794/0001213900-26-007794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390026007794/ea0273451-8k_nkgen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-007794
- JSON: https://secwatch.observer/filing/0001213900-26-007794.json
- Plain text: https://secwatch.observer/filing/0001213900-26-007794.txt

## Key facts
- Material Agreements
  NKGen Biotech, Inc. amended FPA Amendment with Seller (Meteora Strategic Capital, LLC, Meteora Capital Partners, LP, and Meteora Select Trading Opportunities Master, LP) (effective 2026-01-20).
  - Action: amendment
  - Counterparty: Seller (Meteora Strategic Capital, LLC, Meteora Capital Partners, LP, and Meteora Select Trading Opportunities Master, LP)
  - Effective: 2026-01-20
  source text: On January 20, 2026, NKGen Biotech, Inc. (the “Company” and formerly known as Graf Acquisition Corp. IV) and Seller (defined below) entered into an eighth amendment (the “FPA Amendment”) to the forward purchase agreement, dated as of September 22, 2023 (the “FPA”), initially among the Company, Graf, Meteora Strategic Capital, LLC (“MSC”), Meteora Capital Partners, LP (“MCP”) and Meteora Select Trading Opportunities Master, LP (“MSTO” with MSC, MCP, and MSTO collectively, “Seller”) for OTC Equity Prepaid Forward Transactions, as amended on December 26, 2023, as further amended on January 2, 2024, January 11, 2024, February 21, 2024, July 12, 2024, September 5, 2024, and December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026007794/0001213900-26-007794-index.htm
- Material Agreements
  NKGen Biotech, Inc. amended Alpine Second Amendment with AlpineBrook Capital GP I Limited valued at $372,000 (effective 2026-01-23).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: AlpineBrook Capital GP I Limited
  - Value: $372,000
  - Effective: 2026-01-23
  source text: On January 23, 2026, the Company and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a second amendment (the “Alpine Second Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026 (the “Note”). The Alpine Second Amendment provides an additional $372,000 of funding to the Borrowers (the “Third Additional New Loan”). As a result, the principal amount of the Note was increased to $26,507,106.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026007794/0001213900-26-007794-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.